INVENTURUS KNOWLEDGE SOLUTIONS LIMITED — Investor Presentation 2025

May 15, 2025

May 15, 2025

BSE Limited

The Listing Department Phiroze Jeejeebhoy Towers 25[th] Floor, Dalal Street Fort, Mumbai 400 001 Maharashtra, India

National Stock Exchange of India Limited

The Listing Department Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex Bandra (East), Mumbai 400051 Maharashtra, India

BSE Scrip Code: 544309

NSE Symbol: IKS

Dear Sir/Ma’am,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith investor presentation on the financial results of the Company for the quarter and financial year ended March 31, 2025.

The presentation is also being uploaded on the website of the Company at the - https://ikshealth.com/investor relations/

Request you to take it on record and disseminate it on your website.

Thanking you.

Yours sincerely,

For Inventurus Knowledge Solutions Limited

Sameer Digitally signed by Sameer Shashikant Shashikant Chavan Date: 2025.05.15 Chavan 21:48:43 +05'30'

Sameer Chavan

Company Secretary and Compliance Officer Membership No. F7211

Encl: As above

IKS Health

Q4 FY 25 Investor Presentation

==> picture [76 x 29] intentionally omitted <==

==> picture [137 x 139] intentionally omitted <==

1

Disclaimer

==> picture [75 x 29] intentionally omitted <==

This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the statements themselves. Such statements comprise the company’s current visibility on market movements, client discussions, and related factors. Inventurus Knowledge Solutions Limited does not assume an obligation to update or revise any forward-looking statements.

2

IKS Health - a comprehensive healthcare enablement platform empowering provider organizations

==> picture [75 x 29] intentionally omitted <==

Total Addressable Market1,2				US$5tn US Healthcare Expenditure (CY2024)		US$222bn / US$34bn TAM / Outsourced Market (CY2023) (Now expanded TAM by another $50B approx.)		8% / 12% TAM / Outsourced Market CAGR (2023-2028E)	The only
Established Client Relationships				700+/850+ Healthcare Organizations FY 2025/FY 2024		90+% Revenues from Repeat Customers (FY25)		5+ Years Top 10 / Top 5 Clients Average Vintage (As of March 31, 2025) Comprehensive platform that delegates all chores across the patient journey Adding a technology-enabled layer to ‘care delivery pyramid’ to help
Specialised workforce				12,661 / 2,294 Employees / Clinically trained staff (As of March 31, 2025)		473 Technology Focused Employees (As of March 31, 2025)		55 Sales & Marketing Employees (As of March 31, 2025) Physician Enterprises achieve increased revenue and reduced expenses

Note: Numbers Rounded off to nearest Integer / percent; 1. Source: Zinnov Report; 2. TAM- Total Addressable Market for RCM, VBC, Patient, Coding and Client Services. 3. Repeat clients refers to clients who availed our platform or solutions during the previous period, and revenue generated from such clients are calculated for the relevant period

3

IKS Health enables care transformation across the patient journey

==> picture [75 x 29] intentionally omitted <==

==> picture [666 x 304] intentionally omitted <==

----- Start of picture text -----

Automation Level Automation Level Automation Level Automation Level
Optimized Patient Patient Prospective
Pre-Visit
Scheduling Financial Engagement Clinical Chart
Clearance Hub Reviews
Automation Level Automation Level Automation Level Automation Level
Tech-led Referral Order
IKS Scribble [TM] Pre-Visit Peri-Visit
Coding Management
Summary
Automation Level Automation Level Automation Level Automation Level
Post-Visit Billing & Denial Payment Concurrent & Patient AR
Prevention Posting & Denial Denovo Risk
Management
Management Coding
Automation Level Automation Level Automation Level Automation Level
Care Management Inbox IKS AssuRx [TM] IKS Stacks [TM] In-between Visits
& UM Management
Automation Level Automation Level Automation Level Automation Level Automation Level
Clinical Revenue Medico-legal
In-acute Settings Documentation Clinical Optimization Documentation Discharge
Solutions Coding & CDI Solutions Solutions Summary
----- End of picture text -----

Automation Level

==> picture [114 x 11] intentionally omitted <==

----- Start of picture text -----

1 2 3 4 5
----- End of picture text -----

4

$45B+* Equity Investment in HCIT 2021-2024 focused largely on Point Solutions

==> picture [75 x 29] intentionally omitted <==

General catalyst owned Commure acquired Scribing player Augmedix in July 2024 for $139 mn. Its last reported net loss was $(19) million.

R1 RCM was acquired by TowerBrook Capital Partners and Clayton, Dubilier & Rice at a valuation of $ 8.9 bn in Nov 2024. Its last reported revenue was $2.2 bn and net income was $3.3 million in CY 2023.

General catalyst acquired Summa Health system in Nov 24 for $485 mn.

EQT Private Capital Asia acquired a controlling stake in GeBBS Healthcare Solutions from ChrysCapital in Sept 2024 at over $ 850 mn .

New Mountain Capital in Jan 2025 made a strategic investment in Access Healthcare - an RCM Company.

Innovaccer raised $275 mn in Jan 2025 led by B Capital , Generation Investment Management , M12 among other investors at a valuation of $3.45 bn .

Abridge raised $400 mn in 2024 and early 2025 led by Lightspeed and IVP ventures among other investors at a latest valuation of $2.75 billion .

KKR & Co in May 2024 acquired a significant minority stake for $ 165 mn in Infinx . Northwest Venture partners , an existing shareholder also participated in the transaction.

Raised $70 million led by Zoom along with a platform deal to Integrate AI into Zoom’s Clinical Workflow Solution

Global funds including Blackstone, General Atlantic and TPG looking to buy AGS Health for approx. $1 billion

5

* As per S&P global report

Q4 - Strong growth while delivering continuous margin expansion

==> picture [75 x 29] intentionally omitted <==

==> picture [669 x 271] intentionally omitted <==

----- Start of picture text -----

Deep Client Globally Diversified
Growth At Scale Strong Margin Profile
Relationships Workforce
INR 7240 mn 450+ 31% 12,661
Revenue from Enterprise level EBITDA Total Employees
Operations customers
17% INR 2,842 mn / 39% 20% 2,294 / 473
YoY growth in INR Revenue from Top 10 PAT Margin Clinical /tech focussed
customers employees
13% 6.23 / 5.67 years 68%/133%
49%
YoY growth in USD Top 10 / Top 5 Clients YoY growth in
Women employees
Average Vintage EBITDA/PAT
----- End of picture text -----

6

Key Client Wins including 3 large platform deals

==> picture [75 x 29] intentionally omitted <==

==> picture [91 x 20] intentionally omitted <==

Community owned health system in Oregon

Implementation of the IKS Health care enablement platform at Sky Lakes to deliver outstanding care and ensure financial sustainability across hospital and clinical settings

Multi-specialty group with 100 providers across 20 locations in Washington State

Expanded partnership with Western Washington Medical Group to implement the IKS care enablement platform to enhance care delivery, improve financial outcomes and invest in growth

==> picture [87 x 28] intentionally omitted <==

Largest independent gastroenterology (GI) services organization in world

Strategic partnership with GI Alliance to optimize clinical and financial processes through the IKS care enablement platform to deliver high quality care and accelerate growth

==> picture [110 x 32] intentionally omitted <==

Expanded partnership with Platinum Dermatology Partners to implement the full breadth of the IKS Health care enablement platform

Leading clinical dermatology platform

==> picture [97 x 28] intentionally omitted <==

Leading orthopedic and pain management practice in New York

Expanded alliance with OrthoNY to cover patient engagement hub and revenue cycle management to deploy AI-powered personalized digital strategies to deliver exceptional patient experience

7

Awards and Recognition

==> picture [75 x 29] intentionally omitted <==

==> picture [62 x 64] intentionally omitted <==

IKS Health Received 2 New Recognitions in Black Book Research 2025 Rankings

IKS Health has been ranked #1 in Clinical Documentation for the 12th consecutive year and #1 in Medical Coding for the 3rd year in a row. These accolades follow our recent achievement of #1 Ranking in the AI-driven Revenue Cycle Management (RCM) category, further solidifying our leadership in the healthcare industry.

==> picture [62 x 64] intentionally omitted <==

IKS Health Wins Top Honors in AI-Driven RCM Category in the 2025 Black Book Survey

IKS Health won top honors in the 2025 Black Book Research report for AI-driven Revenue Cycle Management (RCM).

==> picture [62 x 61] intentionally omitted <==

2025 Best in KLAS

for Medical Transcription Services - February 2025

==> picture [70 x 50] intentionally omitted <==

HITRUST r2 Certification demonstrates that IKS has met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk.

8

Q4 FY25: Growing faster than market with improving margins

==> picture [75 x 29] intentionally omitted <==

==> picture [605 x 334] intentionally omitted <==

----- Start of picture text -----

Revenue EBITDA
INR Mn INR Mn
2,262
7,240 16.8% YoY 2,006 68.2% YoY
6,572
6,200
1,344
31.2%
10.2% QoQ 30.5% 12.7% QoQ
21.7%
Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25
PAT
Adjusted PAT
INR Mn
INR Mn
1,478
1,646
1,297 132.5% YoY 1,455
108.2% YoY
790 22.7%
636 20.4%
19.7% 14.0% QoQ 22.1%
13.1% QoQ
10.3% 12.8%
Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25
----- End of picture text -----*

*Adjusted PAT is adjusted for amortization of intangible assets recognised on acquisition which is a non-cash expense

9

Q4 FY25 - Improving EPS and maintaining high ROE

==> picture [75 x 29] intentionally omitted <==

==> picture [139 x 31] intentionally omitted <==

----- Start of picture text -----

EPS ₹
----- End of picture text -----

==> picture [76 x 70] intentionally omitted <==

----- Start of picture text -----

131.5% YoY
13.9% QoQ
----- End of picture text -----

==> picture [216 x 269] intentionally omitted <==

----- Start of picture text -----

ROE %
----- End of picture text -----

EPS is calculated as profit for the period divided by weighted average number of equity shares as defined in IND AS 33.

Return on Equity is calculated as profit for the period divided by total equity at the end of the period.

10

FY25 - Strong growth while delivering continuous margin expansion

==> picture [75 x 29] intentionally omitted <==

==> picture [669 x 271] intentionally omitted <==

----- Start of picture text -----

Deep Client Globally Diversified
Growth At Scale Strong Margin Profile
Relationships Workforce
INR 26,640 mn 450+ 30% 12,661
Revenue from Enterprise level EBITDA Total Employees
Operations customers
47% INR 9,230 mn / 35% 18% 2,294 / 473
YoY growth in INR Revenue from Top 10 PAT Margin Clinical /tech focused
customers employees
44% 6.20 / 8.57 years 50%/31%
49%
YoY growth in USD Top 10 / Top 5 Clients YoY growth in
Women employees
Average Vintage EBITDA/PAT
----- End of picture text -----

11

FY25: Strong EBITDA and PAT growth

==> picture [75 x 29] intentionally omitted <==

==> picture [605 x 331] intentionally omitted <==

----- Start of picture text -----

Revenue EBITDA
INR Mn INR Mn
26,640
7,911
18,179
5,287
46.5% YoY 49.6% YoY
28.5% 29.5%
29.1% 29.7%
FY 24 FY 25 FY 24 FY 25
PAT
Adjusted PAT
INR Mn
INR Mn
4,861
5,504
3,705
3,961
31.2% YoY
38.9% YoY
20.4% 18.2%
21.8% 20.7%
FY 24 FY 25 FY 24 FY 25
----- End of picture text -----*

*Adjusted PAT is adjusted for amortization of intangible assets recognised on acquisition which is a non-cash expense

12

FY 25 - Improving EPS and maintaining high ROE

==> picture [75 x 29] intentionally omitted <==

==> picture [218 x 269] intentionally omitted <==

----- Start of picture text -----

EPS ₹
29
22 30.6% YoY
FY 24 FY 25
----- End of picture text -----

==> picture [216 x 269] intentionally omitted <==

----- Start of picture text -----

ROE %
----- End of picture text -----

EPS is calculated as profit for the period divided by weighted average number of equity shares as defined in IND AS 33.

Return on Equity is calculated as profit for the period divided by total equity at the end of the period.

13

FY 25 - Strong cash generation supporting growth aspirations

==> picture [253 x 269] intentionally omitted <==

----- Start of picture text -----

OCF & FCF
INR Mn
43.2% OCF
55.6% FCF
----- End of picture text -----

==> picture [139 x 31] intentionally omitted <==

----- Start of picture text -----

Net Debt
INR Mn
----- End of picture text -----

==> picture [75 x 29] intentionally omitted <==

Reported OCF and FCF are impacted by upfront guarantee payment of economic value add made to a new customer, Palomar for Rs 1,390 mn in FY 25 and acquisition related payments in FY 24

14

Financials - Summary INR millions

==> picture [75 x 29] intentionally omitted <==

INR Mn

Particulars	Q4 FY 25	Q3 FY 25	QoQ%	Q4 FY 24	YoY%	FY 25	FY 24	YoY%
Revenue	7,240	6,572	10.2%	6,200	16.8%	26,640	18,179	46.5%
Other Income - Operating*	-	134	-100.0%	73	-100.0%	176	73	141.2%
Forex Gain/ (Loss)	(24)	58	-141.2%	24	-199.6%	38	(22)	-270.1%
Employee benefit expense excluding ESOP	3,749	3,769	-0.5%	3,772	-0.6%	14,669	9,533	53.9%
Other Expenses	1,089	923	17.9%	1,145	-4.9%	3,997	3,324	20.2%
Adjusted EBITDA	2,378	2,071	14.8%	1,379	72.5%	8,188	5,372	52.4%
Adjusted EBITDA %	32.8%	31.5%	1.3%	22.2%	10.6%	30.7%	29.6%	1.2%
ESOP Cost	116	64	80.4%	34	237.5%	277	86	224.0%
EBITDA	2,262	2,006	12.7%	1,344	68.2%	7,911	5,287	49.6%
EBITDA %	31.2%	30.5%	0.7%	21.7%	9.6%	29.7%	29.1%	0.6%
Finance cost	210	205	2.3%	322	-34.7%	898	601	49.4%
Depreciation and amortisation	283	278	2.1%	274	3.5%	1,127	585	92.4%
Interest income	33	78	-58.3%	60	-45.7%	176	316	-44.2%
Profit before exceptional items and tax	1,801	1,602	12.4%	809	122.7%	6,063	4,417	37.3%
Profit before exceptional items and tax %	24.9%	24.4%	0.5%	13.0%	11.8%	22.8%	24.3%	-1.5%
Tax expense	323	305	5.9%	173	86.7%	1,202	712	68.9%
Profit for the period	1,478	1,297	14.0%	636	132.5%	4,861	3,705	31.2%
Profit for the period %	20.4%	19.7%	0.7%	10.3%	10.2%	18.2%	20.4%	-2.1%
Amortisation of Intangible assets	168	158	6.0%	155	8.5%	643	257	150.6%
Adjusted Profit for the period	1,646	1,455	13.1%	790	108.2%	5,504	3,961	38.9%
Adjusted Profit for the period %	22.7%	22.1%	0.6%	12.8%	10.0%	20.7%	21.8%	-1.1%

• Includes decrease in fair valuation of contingent consideration which is an operating income in nature. Corresponding increase, if any in contingent consideration is also recorded in Other expense impacting the EBITDA.

15

Other KPI Metrics - Yearly

==> picture [75 x 29] intentionally omitted <==

Particulars	FY 25	FY 24**
Adjusted EBITDA per employee*	0.63	0.54
Revenue from Top 10 customers INR mn	9,230	7,937
Contribution from Top 10 customers	34.6%	43.7%
Revenue from Top 5 customers INR mn	5,828	5,016
Contribution from Top 5 customers	21.9%	27.6%
Ageing of Top 10 clients (number of years)	6.20	6.04
Ageing of Top 5 clients (number of years)	8.57	8.00
FCF Yield	56.7%	47.8%
Clients with revenue >$1mn	69	40

• For calculation of Adjusted EBITDA, see slide 15.

** FY 24 includes 5 months of Aquity. Hence numbers may not be comparable

16

Other KPI Metrics - Quarterly

==> picture [75 x 29] intentionally omitted <==

Particulars Q4 FY 25 Q3 FY 25 Q4 FY 24 Annualised Adjusted EBITDA per employee in INR mn 0.76 0.61 0.41 Revenue from Top 10 customers INR mn 2,842 2,724 2,185 Contribution from Top 10 customers 39.3% 41.5% 35.2% Revenue from Top 5 customers INR mn 1,944 1,806 1,370 Contribution from Top 5 customers 26.9% 27.5% 22.1% Ageing of Top 10 clients (number of years) 6.23 7.32 6.17 Ageing of Top 5 clients (number of years) 5.67 7.73 6.29

17

==> picture [139 x 140] intentionally omitted <==

Join the Movement Grow, Scale, Thrive

==> picture [720 x 63] intentionally omitted <==